Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Enterocutaneous fistula

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Enterocutaneous fistula. Displaying page 1 of 1.
    EudraCT Number: 2013-003998-10 Sponsor Protocol Number: 46334 Start Date*: 2013-12-06
    Sponsor Name:Academic medical center
    Full Title: A randomized clinical trial investigating Lanreotide For output reduction in patients with high-output Enterocutaneous fistula
    Medical condition: All adult patients with a small bowel fistula with an output > 500ml/day or a an enterostomy with an output > 1500ml/day after gastro-intestinal, abdominal wall surgery. Randomization is possible i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019973-13 Sponsor Protocol Number: CQAX576A2209 Start Date*: 2011-01-14
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, randomized, double-blind, active controlled study to assess efficacy, safety and tolerability of the anti-IL13 monoclonal antibody QAX576 in the treatment of perianal fistulas in pa...
    Medical condition: Treatment of perianal fistulas in patients suffering from Crohn's Disease.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10016717 Fistula PT
    14.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003153-15 Sponsor Protocol Number: GS-US-419-4016 Start Date*: 2017-08-01
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn’s Disease
    Medical condition: Perianal Fistulizing Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10075465 Fistulizing Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) DE (Completed) PL (Completed) ES (Completed) AT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003090-34 Sponsor Protocol Number: 1368-0008 Start Date*: 2019-02-05
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: Mechanism of Action and Clinical Effect of BI 655130 in Patients with fistulizing Crohn’s Disease
    Medical condition: Fistulizing Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10075465 Fistulizing Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) DE (Completed) NL (Prematurely Ended) HU (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005363-28 Sponsor Protocol Number: AST001 Start Date*: 2006-07-11
    Sponsor Name:Ocera Therapeutics, Inc.
    Full Title: A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF AST-120 IN MILD TO MODERATELY ACTIVE CROHN’S PATIENTS WITH FISTULAS
    Medical condition: The two main categories of inflammatory bowel disease (IBD) are ulcerative colitis and Crohn’s disease. Crohn’s disease is characterized by recurring episodes of suppurative inflammation of any par...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) BE (Completed) DE (Completed) HU (Completed) AT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:18:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA